In addition, almost all of the nine studies included in our review included patients with advanced-stage cancers (stage III-IV), and that PD-1/PD-L1 checkpoint inhibitors were used as first-line treatment or as second- or third-line treatments. This evidence concerns the gene PDCD1 and cancer.